JCAR020 / BMS, Memorial Sloan-Kettering Cancer Center, Eureka Therap - LARVOL DELTA

HIV immune evasin Nef enhances allogeneic CAR T cell potency. (PubMed, Nature) - "HIV-1 Nef uniquely also acts through the serine-threonine kinase Pak2 to abate activation-induced cell death and promote survival of CAR T cells in vivo. Thus, virus-like immune escape can harness multiple mechanisms that act in concert to enhance the therapeutic efficacy of allogeneic CAR T cells."

Journal • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Multiple Myeloma • Oncology • CD8 • PAK2

Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors (clinicaltrials.gov) - P1 | N=18 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Aug 2024 ➔ Aug 2025 | Trial primary completion date: Aug 2024 ➔ Aug 2025

Trial completion date • Trial primary completion date • Oncology • Ovarian Serous Adenocarcinoma • Solid Tumor • PD-L1

Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors (clinicaltrials.gov) - P1 | N=18 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Aug 2023 ➔ Aug 2024 | Trial primary completion date: Aug 2023 ➔ Aug 2024

Trial completion date • Trial primary completion date • Oncology • Ovarian Serous Adenocarcinoma • Solid Tumor • PD-L1

[VIRTUAL] A phase I clinical trial of autologous chimeric antigen receptor (CAR) T cells genetically engineered to secrete IL-12 and to target the MUC16ecto antigen in patients (pts) with MUC16ecto+ recurrent high-grade serous ovarian cancer (HGSOC) (SGO-I 2020) - P1 | "An additional cohort was treated at dose level 3 (3 × 106 CAR T cells/kg) following pretreatment with cyclophosphamide/fludarabine... IV and IP IL-12 secreting MUC16ecto-targeted CAR T cells were safely administered in the absence of chemotherapy. Toxicity was observed when the CAR T cells were given post-lymphodepleting chemotherapy. Dose escalation of CAR T cells will continue to dose level 5 (3 × 107 CAR T cells/kg)."

Clinical • P1 data • Gynecologic Cancers • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • Ophthalmology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor

Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors (clinicaltrials.gov) - P1 | N=18 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Aug 2022 ➔ Aug 2023 | Trial primary completion date: Aug 2022 ➔ Aug 2023

Trial completion date • Trial primary completion date • Oncology • Ovarian Serous Adenocarcinoma • Solid Tumor • PD-L1

A phase I clinical trial of autologous chimeric antigen receptor (CAR) T cells genetically engineered to secrete IL-12 and to target the MUC16ecto antigen in patients (pts) with MUC16ecto+ recurrent high-grade serous ovarian cancer (HGSOC) (SGO 2020) - P1; "An additional cohort was treated at dose level 3 (3 × 106 CAR T cells/kg) following pretreatment with cyclophosphamide/fludarabine... IV and IP IL-12 secreting MUC16ecto-targeted CAR T cells were safely administered in the absence of chemotherapy. Toxicity was observed when the CAR T cells were given post-lymphodepleting chemotherapy. Dose escalation of CAR T cells will continue to dose level 5 (3 × 107 CAR T cells/kg)."

Clinical • P1 data • Gynecologic Cancers • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • Ophthalmology • Ovarian Cancer • Solid Tumor • CA125 • EGFR • IL12A

Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors (clinicaltrials.gov) - P1; N=18; Active, not recruiting; Sponsor: Memorial Sloan Kettering Cancer Center; Recruiting ➔ Active, not recruiting; N=30 ➔ 18; Trial completion date: Aug 2021 ➔ Aug 2022; Trial primary completion date: Aug 2021 ➔ Aug 2022

Clinical • Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Oncology • Ovarian Serous Adenocarcinoma • Solid Tumor • PD-L1

"@DrPaulyDeSantis @dan_smithey $JUNO catalysts updated" - dough, @tgtxdough

Anticipated P1 data • Anticipated P1/2 data • Tweet • Hematological Malignancies • Oncology

Juno Therapeutics reports fourth quarter and 2015 financial results (Juno Press Release) - "The Phase II ROCKET trial for JCAR015...continues to enroll adult r/r ALL patients in a potential U.S. registration trial that could lead to product approval as early as 2017...Juno began enrollment of a multi-center Phase I trial for JCAR017 in r/r NHL and expects enrollment to continue through 2016...Juno also expects to begin a Phase I trial for its CD19/4-1BB ligand armored CAR in 2016...Juno began trials for solid tumor product candidates...JCAR024 (ROR-1-directed CAR T), JCAR020 (MUC-16-directed armored CAR T engineered to secrete IL-12), JCAR023 (L1-CAM-directed CAR T), and JTCR016 (WT-1- directed TCR)...with data expected over the next 6-18 months."

Anticipated clinical data • Anticipated enrollment status • Anticipated regulatory • Enrollment open • Hematological Malignancies • Oncology

Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors (clinicaltrials.gov) - P1; N=30; Recruiting; Sponsor: Memorial Sloan Kettering Cancer Center; Trial completion date: Aug 2020 ➔ Aug 2021; Trial primary completion date: Aug 2020 ➔ Aug 2021

Clinical • Trial completion date • Trial primary completion date • Oncology • Solid Tumor • PD-L1